Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Obesity

    Valdosta, GA

    Search
    Obesity
    Valdosta, GA
    Show Map
    Map View
    Valdosta, GA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      111 Obesity Trials near Valdosta, GA

      Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Sisters of Heart for Improving Heart Health

      Ellenton, Georgia
      The goal of this hybrid Type 1 effectiveness-implementation trial is to test the extent to which a peer support and community resource navigation intervention improves psychological well-being, addresses social determinants of health and thus reduces cardiometabolic risk among rural, migrant, low-income farmworker women aged 18-45 years. The main questions it aims to answer are: * If and to what extent does the intervention reduce stress, social isolation, and psychological distress by improving social support and access to needed resources? * If and to what extent does the intervention improve cardiometabolic health, measured by the American Heart Association's Life's Essential 8 (LE8) score? Researchers will compare the CHW-led Sisters of Heart (Hermanas de Corazón) intervention to a Basic intervention (LE8 assessment and resource information) to assess the effect of peer support and community resource navigation on heart health outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Neurologic Disorder, Others

      250 Participants Needed

      CX11 for Obesity

      Thomasville, Georgia
      This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Heart Problems, Cancer, Others
      Must Not Be Taking:GLP-1 Receptor Agonists

      250 Participants Needed

      RGT001-075 for Obesity

      Thomasville, Georgia
      This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Pancreatitis, Gallbladder Disease, Others
      Must Not Be Taking:GLP-1 Analogs

      236 Participants Needed

      CT-388 for Type 2 Diabetes and Obesity

      Thomasville, Georgia
      This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Retinopathy, Neuropathy, Others
      Must Be Taking:Metformin, SGLT-2 Inhibitors

      360 Participants Needed

      Tirzepatide for Psoriatic Arthritis

      Waycross, Georgia
      The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Thyroid Cancer, Others
      Must Be Taking:Ixekizumab

      200 Participants Needed

      Petrelintide for Obesity and Type 2 Diabetes

      Lake City, Florida
      The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Hypoglycemia, Obesity Surgery, Others
      Must Be Taking:Metformin, SGLT2 Inhibitors

      216 Participants Needed

      Semaglutide for Obesity

      Tallahassee, Florida
      The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:12 - 15

      Key Eligibility Criteria

      Disqualifiers:Prepubertal, Obesity Surgery, Diabetes, Others
      Must Be Taking:Semaglutide

      500 Participants Needed

      Inspiratory Muscle Training for Obesity

      Tallahassee, Florida
      The purpose of this study is to determine whether inspiratory muscle strength training reduces blood pressure in adults with obesity.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Neurological, Renal, Others
      Must Not Be Taking:Tobacco, Nicotine

      44 Participants Needed

      Exercise for Obesity

      Tallahassee, Florida
      Impaired endothelial function is observed in disease states related to obesity, such as atherosclerosis, coronary artery disease, and diabetes. Reactive oxygen species (ROS) production and resultant oxidative stress contribute to the development of these obesity-related diseases. The enzyme NADPH-oxidase is a major source of oxidative stress within the vasculature, and has been linked with the Metabolic Syndrome. In the investigator's previously funded studies, the investigators demonstrated for the first time that: 1) in vivo ROS were elevated in skeletal muscle of obese as compared to lean or overweight human subjects, 2) perfusion of the NADPH-oxidase inhibitor apocynin locally into muscle normalized ROS levels and reversed local microvascular endothelial dysfunction in the obese individuals, and 3) aerobic exercise training was effective at attenuating in vivo hydrogen peroxide production and reversing microvascular endothelial dysfunction in the obese individuals. The investigators will investigate in this R15 renewal application the mechanism of exercise training-induced alterations in ROS production and action on endothelial dysfunction in obesity using our newly developed microdialysis methodology of monitoring ROS production, in combination with analysis of muscle biopsy samples obtained before and after our previously tested 8-week intervention of aerobic interval exercise training. The objectives of this study are to determine the impact of in vivo NADPH oxidase activity on endothelial function in obese individuals, and to determine the mechanism of training-induced improvements in endothelial function. The investigator's unique microdialysis methodology will allow monitoring of microvascular/endothelial function and ROS generation, as well as the administration of pharmacological agents directly into muscle. The central hypothesis is that it is upregulation of both mitochondrial ROS and NADPH oxidase-derived ROS that results in endothelial dysfunction in obesity, and that exercise training down-regulates mitochondrial-derived ROS, and NADPH oxidase 4, thereby improving endothelial function. The aims of this proposal are to: 1) determine the contributions of mitochondrial ROS and specific NADPH oxidase isoforms to the NADPH oxidase dependent endothelial dysfunction in skeletal muscle of obese individuals; 2) determine the mechanism of ROS reduction and improved endothelial function resulting from an 8-week aerobic interval training program.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Heart Failure, Others
      Must Be Taking:Estrogen/progestin Contraceptives

      25 Participants Needed

      Low Oxygen Exposure for Obesity

      Tallahassee, Florida
      The objective of the proposed double-blind, parallel-arm, randomized clinical trial is to evaluate changes in body weight and composition, assess determinants of energy balance (intake and expenditure), and measure modulators of energy balance, following 8 wk of calorie restriction (-500 kcal/d) in combination with either overnight exposure to normobaric hypoxia (8 h/night, 15% FiO2, \~2640 m) or normoxia (8 h/night, 21% FiO2), using a commercially available, in-home tent system, in adults with obesity.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 65

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Gastrointestinal, Kidney, Others
      Must Not Be Taking:Sedatives, Sleeping Aids, Tranquilizers, Others

      60 Participants Needed

      Almonds for Overweight Active Older Adults

      Tallahassee, Florida
      The overall objective of this proposed randomized, crossover study is to determine the effect of 12 weeks of almond consumption, ingested as a snack twice daily, on energy expenditure, performance and functional related outcomes, in active, overweight, older adults, in comparison to 12 weeks of an isocaloric matched control snack. The central hypothesis of this study is, due to the nutritionally beneficial composition of almonds, that daily consumption of an almond snack for 12 weeks will contribute to improvements in energy expenditure, physical and functional performance, vascular function, inflammation/oxidative stress, sleep quality, mood status, and body composition in active, overweight and obese older adults compared to an isocaloric commercially available snack.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50 - 59

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Diseases, Type 2 Diabetes, Others
      Must Not Be Taking:Antihypertensives

      50 Participants Needed

      Exercise Training for Fat Metabolism in Postmenopausal Women

      Tallahassee, Florida
      Adipose tissue turnover plays a critical role in body weight maintenance, and obesity is underscored by the dysregulated balance between fat breakdown and synthesis. Although there are clear health-related benefits of physical activity, little is known about how resistance exercise, as opposed to endurance exercise, can reduce the risk of metabolic disorders, particularly in women. The goal of the proposed study is to investigate the effectiveness of resistance training to improve basal and stimulated fat metabolism in postmenopausal women with obesity and pre-diabetes, potentially serving as a viable and practical approach to prevent the onset of type 2 diabetes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50 - 75
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Cancer, Cardiovascular, Others
      Must Not Be Taking:Lipid Metabolism Drugs

      120 Participants Needed

      Watermelon for Obesity

      Tallahassee, Florida
      The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are: 1. Will consuming fresh watermelon daily for 6-weeks will improve intestinal barrier health and increase microbiome diversity such as an increased population of beneficial 'probiotic' bacteria when compared to control participants consuming a low-fat snack? 2. Will consuming fresh watermelon daily for six-weeks will improve other health measures, including body-composition, blood pressure, blood vessel function, blood lipid profiles, and measures of inflammation, as compared to control participants consuming a low-fat snack for the same time period?
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 30

      Key Eligibility Criteria

      Disqualifiers:Tobacco, Marijuana, Cardiovascular, Gastrointestinal, Others
      Must Not Be Taking:Antibiotics, Prebiotics, Probiotics, Postbiotics

      36 Participants Needed

      Time-Restricted Eating for Cognitive Health in Obesity

      Gainesville, Florida
      Grounded in the principles of geroscience, the proposed Fasting ENHANCE study will test whether a time restricted eating (TRE) regimen can improve cognitive function and other aspects of successful aging in a safe and sustainable manner in at risk overweight older adults. Specifically, this study will evaluate whether TRE can improve cognitive and physical function, as well as self-reported sleep, mood, and quality of life, in overweight, older adults (age \> 65 years) who are at high risk of cognitive decline due to self-reported cognitive difficulties. Eligible participants will be assigned to either a TRE intervention, in which they will be instructed to fast for a target of 16 hours per day, or a successful aging (SA) comparison group for a 24-week period.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Diabetes, Cancer, Others
      Must Not Be Taking:Antidepressants, Antipsychotics, Antibiotics, Others

      52 Participants Needed

      BI 456906 for Diabetes and Obesity

      Gainesville, Florida
      This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Gastric Issues, Pancreatitis, Thyroid Cancer, Others
      Must Be Taking:Diet, Exercise

      755 Participants Needed

      BI 456906 for Obesity

      Gainesville, Florida
      This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 2 Diabetes, Heart Failure, Others
      Must Not Be Taking:Obesity Medications, Glucose-lowering Agents

      726 Participants Needed

      Setmelanotide for Hypothalamic Obesity

      Gainesville, Florida
      This trial tests if Setmelanotide, an injection, can help reduce weight and hunger in patients aged 4 and older with acquired Hypothalamic Obesity. The medication works by targeting brain pathways that control hunger and energy use. Setmelanotide has been approved for treating obesity in rare genetic conditions and is being developed for other obesity-related disorders.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4+

      Key Eligibility Criteria

      Disqualifiers:Prader-Willi, ROHHADNET, Severe Psychiatric, Others

      120 Participants Needed

      CagriSema for Obesity

      Jacksonville, Florida
      This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetes

      600 Participants Needed

      Maridebart Cafraglutide for Obesity

      Jacksonville, Florida
      The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Endocrine Disorders, Pancreatitis, Others

      3853 Participants Needed

      Ixekizumab + Tirzepatide for Psoriatic Arthritis

      Jacksonville, Florida
      The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:T1DM, Obesity Surgery, IBD, Others
      Must Not Be Taking:Insulin, IL-17 Inhibitors

      250 Participants Needed

      Why Other Patients Applied

      "I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."

      DK
      Obesity PatientAge: 56

      "I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."

      JP
      Obesity PatientAge: 44

      "I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."

      KI
      Obesity PatientAge: 69

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."

      MW
      Parent of PatientAge: 46
      Match to a Obesity Trial

      Orforglipron for Type 2 Diabetes and Obesity

      Jacksonville, Florida
      This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Others
      Must Be Taking:Oral Antihyperglycemics

      2749 Participants Needed

      Tirzepatide for Obesity

      Jacksonville, Florida
      This trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Recent MI, Pancreatitis, Others

      15374 Participants Needed

      Tirzepatide for Hot Flashes

      Jacksonville, Florida
      The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:46 - 60
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Renal Impairment, Thyroid Issues, ASCVD Risk, Others
      Must Not Be Taking:Hormone Therapy, Estrogens, Antidepressants, Antipsychotics

      40 Participants Needed

      GLP-1 Agonists for Obesity in Menopause

      Jacksonville, Florida
      In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 4
      Age:46 - 60
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Cardiovascular Disease, Hypertension, Others
      Must Not Be Taking:Anti-obesity Medications

      30 Participants Needed

      Semaglutide for Obesity

      Jacksonville, Florida
      This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bariatric Surgery, Untreated Psychiatric, Pregnancy, Others
      Must Not Be Taking:Anti-obesity, GLP1R Agonists

      135 Participants Needed

      GZR18 vs Tirzepatide for Obesity

      Jacksonville, Florida
      This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Renal Impairment, Depression, Others
      Must Not Be Taking:Antidepressants, Antipsychotics, Mood Stabilizers, Others

      285 Participants Needed

      NA-931 and Tirzepatide for Obesity

      Jacksonville, Florida
      A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2
      Age:19 - 80

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Chronic Infections, Others
      Must Not Be Taking:Antidiabetics, Obesity Medications

      224 Participants Needed

      Bimagrumab + Tirzepatide for Obesity

      Jacksonville, Florida
      The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Heart Failure, Others
      Must Not Be Taking:Metformin, Glucose-lowering

      240 Participants Needed

      NT-0796 + Semaglutide for Obesity

      Jacksonville, Florida
      A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Stroke, Coronary Syndrome, Others
      Must Be Taking:Semaglutide

      80 Participants Needed

      NT-0796 for Obesity

      Jacksonville, Florida
      A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:T1DM, Stroke, Heart Failure, Others

      162 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Obesity clinical trials in Valdosta, GA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Obesity clinical trials in Valdosta, GA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Valdosta, GA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Valdosta, GA for Obesity is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Valdosta, GA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Obesity medical study in Valdosta, GA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Obesity clinical trials in Valdosta, GA?

      Most recently, we added Cagrilintide + CagriSema for Childhood Obesity, Cagrilintide for Obesity and Type 2 Diabetes and LY3549492 for Obesity to the Power online platform.

      What is the new treatment for obesity?

      The “new” treatments are weekly injections of GLP-1–based drugs such as semaglutide (Wegovy) and the dual GIP/GLP-1 drug tirzepatide (Zepbound), which curb appetite and slow stomach emptying; in large trials they helped adults lose roughly 15-22 % of their starting weight over 12–18 months when combined with diet and exercise. They are prescription-only, must be used long-term to keep the weight off, and while most side-effects are mild stomach upset, they can be expensive and require close medical follow-up—so you and your clinician should weigh these pros and cons against other options like older pills, bariatric surgery, and structured lifestyle programs.

      How much do I get paid for a clinical trial?

      There is no single rate, but in the U.S. healthy-volunteer Phase I studies usually pay about $75–$150 for a short outpatient visit or $300–$500 per overnight, adding up to roughly $1,500–$6,000 for a multi-day study; later-phase trials for people who already have the illness typically offer a smaller stipend—often $25–$100 per visit—plus travel reimbursement. Amounts are set case-by-case by the study sponsor and ethics board, based on the time you give up, the inconvenience or discomfort involved (blood draws, overnight stays, special diets), and any out-of-pocket costs, and they must be prorated so you can stop at any time and still receive payment for the visits you’ve completed.

      How much weight can you lose with ESG surgery?

      Large studies find that people lose roughly 15–20 % of their starting weight after endoscopic sleeve gastroplasty—about 30–50 lb if you begin at 200–250 lb—and most keep the bulk of that off for at least two years when they stay in a structured nutrition and activity program. Your exact result can be higher or lower depending on your initial BMI, how closely you follow the dietary and lifestyle plan, and whether you attend regular follow-up visits with the bariatric team.

      What weight is considered obese?

      For adults, obesity starts at a body-mass index (BMI) of 30 kg/m²—so take your height in metres, square it, and multiply by 30 to see the weight cut-off. Example: 5′4″ (1.63 m) → 1.63² × 30 ≈ 88 kg / 194 lb; 6′0″ (1.83 m) → 1.83² × 30 ≈ 102 kg / 225 lb. BMI is only a quick gauge—muscle mass, ethnicity, waist size, and other health factors matter too—so use it as a starting point and confirm risks with your healthcare professional.

      Who is eligible for tirzepatide?

      Tirzepatide is eligible for adults in two settings: (1) as Mounjaro to improve blood-sugar control in type-2 diabetes, and (2) as Zepbound for weight management if you have obesity (BMI ≥ 30) or are overweight (BMI ≥ 27) with at least one related condition such as high blood pressure, abnormal cholesterol, sleep apnea, heart disease, or type-2 diabetes. You are NOT a candidate if you’re pregnant, under 18, or have a personal or family history of medullary thyroid cancer or MEN-2; your doctor will also screen for issues like pancreatitis, severe stomach problems, or other risks before prescribing. In short, meeting the diabetes or weight criteria and having no major contraindications makes you a potential candidate, but final approval comes after a thorough medical review.

      What tests are done for unexplained weight gain?

      Doctors usually start with a history and physical exam, then order a small “baseline” panel—complete blood count, comprehensive metabolic panel (kidney + liver), fasting glucose/HbA1c, cholesterol, thyroid-stimulating hormone, and a pregnancy test in women of child-bearing age. If exam findings point to a specific cause, they add focused tests: e.g., cortisol or prolactin for suspected hormone tumors, sex-hormone and ultrasound for possible PCOS, heart or kidney studies for fluid retention, or imaging of the pituitary/adrenal glands. In short, everyone gets the core labs, and any further blood work or scans are chosen only when your symptoms or medications suggest a particular problem.

      Can a morbidly obese person lose weight without surgery?

      Yes. Rigorous studies show that people with class III (“morbid”) obesity can shed 6-8 % of their starting weight through weekly lifestyle-coaching programs, and often 15-20 % when the same program is paired with new once-a-week injections such as semaglutide (Wegovy) or tirzepatide (Zepbound); endoscopic sleeve procedures add another non-surgical option in the same range. Because even a 5-10 % loss markedly improves blood pressure, diabetes and sleep-apnea, doctors usually start with dietitian-guided eating plans, gradual activity and behaviour counselling, then add medication if weight hasn’t dropped by about 5 % after three months—saving surgery for those who still need more help.

      How to get rid of fat deposits on legs?

      You can’t melt fat from your legs alone, so aim for gradual overall weight loss (a modest calorie deficit built around whole foods) while doing both full-body cardio and leg-strength exercises such as squats or lunges 2-3 times a week—the combo burns calories and builds muscle that makes legs look firmer as fat comes off. If your legs stay disproportionately large, painful or bruise easily, ask a clinician about lipedema or other medical causes, because lifestyle changes help most people but specialised treatment is sometimes needed.

      How to get Ozempic for weight loss?

      Ozempic (semaglutide) can be prescribed for weight loss, but it is technically an off-label use; most clinicians instead start with the weight-loss version of the same drug, Wegovy. To pursue either one, confirm you meet typical criteria (BMI ≥30, or ≥27 with a weight-related condition), then see a primary-care doctor, endocrinologist, or an obesity-medicine/telehealth service that can review your labs, rule out contraindications, and submit any required prior-authorization to your insurer or the manufacturer’s savings program. Expect a gradual dose-escalation schedule, routine follow-ups for side-effects such as nausea, and the need to pair the medication with diet and activity changes to maintain the ~15 % average weight loss seen in clinical trials.

      Which drink is good for belly fat loss?

      No drink can “melt” belly fat on its own; losing abdominal fat still comes down to taking in fewer calories than you burn. The most studied helpers are plain water (pre-meal water can curb appetite), unsweetened green tea or black coffee (their caffeine and, for green tea, catechins give a small metabolic boost). Choose these without added sugar, pair them with balanced meals and regular exercise, and they can support—rather than drive—belly-fat loss.

      Popular Searches

      By Condition

      Depression Clinical Trials in Georgia

      Anxiety Clinical Trials in Georgia

      Schizophrenia Clinical Trials in Georgia

      ADHD Clinical Trials in Georgia

      Bipolar Disorder Clinical Trials in Georgia

      Multiple Sclerosis Clinical Trials in Georgia

      Autism Clinical Trials in Georgia

      Treatment Resistant Depression Clinical Trials in Georgia

      Borderline Personality Disorder Clinical Trials in Georgia

      Social Anxiety Disorder Clinical Trials in Georgia

      Parkinson's Disease Clinical Trials in Georgia

      Alzheimer's Disease Clinical Trials in Georgia

      By Location

      Clinical Trials near Atlanta, GA

      Clinical Trials near Augusta, GA

      Clinical Trials near Decatur, GA

      Clinical Trials near Savannah, GA

      Clinical Trials near Marietta, GA

      Clinical Trials near Columbus, GA

      Clinical Trials near Macon, GA

      Clinical Trials near Lawrenceville, GA

      Clinical Trials near Gainesville, GA

      Clinical Trials near Athens, GA

      Clinical Trials near Roswell, GA

      Clinical Trials near Stockbridge, GA

      Other People Viewed

      By Subject

      13 Obsessive Compulsive Disorder Ocd Trials near New York, NY

      Top Clinical Trials near Hawthorne, CA

      Top Clinical Trials near Eureka, IL

      175 Clinical Trials near Hialeah, FL

      Top Clinical Trials near Holmdel, NJ

      Top Clinical Trials near Butler, PA

      Top Orthopedic Clinical Trials

      Top Lung Cancer Clinical Trials near High Point, NC

      Top Acth Clinical Trials

      Top Clinical Trials near Bridgewater, NJ

      Top Obsessive Compulsive Disorder Ocd Clinical Trials near Tampa, FL

      149 Clinical Trials near Springfield, IL

      By Trial

      Bridge Device + Lofexidine for Opioid Use Disorder

      Cryosurgery for Early Stage Lung Cancer

      Tumor Infiltrating Lymphocyte Therapy for Cancer

      Stress Management for Food Insecurity

      Task Practice Interventions for Executive Function

      Endovascular Stent Graft for Aortic Dissection

      Care Transitions Program for Dementia

      BGB-16673 Combination for B-Cell Lymphoma

      Neurostimulation + Therapy for Emotional Regulation Issues

      BI 3032950 for Ulcerative Colitis

      Chemotherapy + Stem Cell Transplant for Fanconi Anemia

      Exercise and Nutrition for Cancer Survivorship